Cardiac Resynchronization Therapy Modular Registry

Giuseppe Ricciardi500 enrolled

Overview

The purpose of the study is to collect some parameters (clinical, electrical, radiographic, echocardiographic and ECG) able to predict response to cardiac resynchronization therapy.

Heart failure is a complex clinical syndrome characterized by a high prevalence and incidence in populations at greatest risk and, therefore, with a significant social and economic impact. Randomized clinical trials, meta-analyzes, observational studies and controlled trials clearly demonstrated that the neuro-hormonal therapy is highly effective in reducing mortality, hospitalization and improving quality of life. In recent years the electrical therapy is playing an increasingly important role in the treatment of patients with chronic heart failure. Such importance is mainly due to the possibility of preventing sudden cardiac death by implanting an ICD and to correct the deleterious effects of electrical dyssynchrony and / or left ventricular mechanics by CRT. The CRT has proven an effective tool in reducing mortality, reducing symptoms and improving quality of life in patients already receiving optimal medical therapy. Despite the undoubted benefits that the electrical treatment has added to conventional medical therapy, a high percentage of patients does not benefit in terms of clinical and echocardiographic. The identification of non-responders to CRT is crucial in order not to submit the patients to an unnecessary and costly device whose electrical therapy proves to be ineffective. The reason for lack of response is still unclear but factors such as lead placement, device-settings and the degree of dyssynchrony before implant seems to be important. The purpose of the study is to collect some parameters (clinical, electrical, radiographic, echocardiographic and ECG) able to predict response to cardiac resynchronization therapy.

Study Type

OBSERVATIONAL

Enrollment

500

Conditions

Heart Failure

Interventions

Cardiac Resynchronization TherapyPROCEDURE

Any commercially available Cardiac Resynchronization Therapy devices with or without defibrillation backup (CRT-D/CRT-P) can be used upon discretion of the investigator according to current guidelines

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Chronic symptomatic HF despite stable, optimal drug therapy * Indication for a cardiac resynchronisation device with or without defibrillator backup according to current guidelines * Patients implanted with cardiac resynchronization device Exclusion Criteria: * Patients participating in other studies that clearly impact the clinical practice of the center * Patients who are unable to provide informed consent * Patients who can not perform follow-up in the center

Locations (12)

Ospedale Degli Infermi

Biella, Biella, Italy

San Giacomo e Cristoforo

Massa, Massa, Italy

Azienda Ospedaliera di Padova

Padova, Padova, Italy

Outcomes

Primary Outcomes

Clinical response

Improvement in functional class status by at least one NYHA Class or remain in functional class II

Time frame: 24 months

Echocardiographic response of absolute increase of ≥5% in LVEF

Patients at follow-up to 6-12 months show an increase of the absolute value of the LVEF than 5%

Time frame: 24 months

Echocardiographic response of ≥15% reduction in LVESV

Patients at follow-up to 6-12 months show a systolic volume (LVESV) reduction greater than 15%

Time frame: 24 months

Secondary Outcomes

LV lead/RV lead geometric distance

To investigate the correlation of LV lead/RV lead geometric distance (as measured by fluoroscopy) and reverse remodeling in cardiac resynchronization therapy (as measured by echocardiography as defined in primary outcome measure) at 12 months. The relation with LVESVi change between baseline and 12 months will be analyzed.

Time frame: 12 months

Change from baseline in R wave in 12-lead ECG at 12 months

To investigate the relationship between the ECG characteristics at baseline and response to cardiac resynchronization therapy (as measured by echocardiography as defined in primary outcome measure) at 12 months. The purpose of this objective is to evaluate the R wave in 12-lead ECG during BIV, RV and LV pacing and change from baseline at 12 months.

Time frame: 12 months

Number of ventricular arrhythmias after cardiac resynchronization therapy

To investigate the relationship between LV pacing and the number of ventricular tachycardia/fibrillation and/or appropriate/inappropriate shocks. The number and type of arrhythmia before and after upgrading to CRT device at 24 months will be analyzed

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.